Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?

The article discusses a study which evaluated pathologic response rates, toxicity, and predictors of response in locally-advanced cervical cancer patients medicated with neoadjuvant cisplatin and paclitaxel after radical surgery. The study administered three cycles of cisplatin and paclitaxel intravenously every three weeks to 14 patients with stage IB2 to IIB cervical cancer. It was said that 86 percent of patients remain disease-free at follow-up. The achievement of an optimal response following neoadjuvant chemotherapy is cited as an important prognostic factor.